WuXi Biologics to sell Ireland-based vaccine site to MSD for $500m
The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.
The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.
What's Your Reaction?
